Page last updated: 2024-12-10

meteneprost

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

meteneprost: 9-deoxo-9-methylene-PGEs are possible solution to PGE stability problem; stable in aqueous media from pH 1 to 14 & have biological properties similar to corresponding PGEs; cpd tested for use as early pregnancy terminater & has low incidence of nausea & gastrointestinal side effects; note that cpd is derivative of both PGE2 & PGF2alpha; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5283060
CHEMBL ID3989772
CHEBI ID165325
SCHEMBL ID564226
MeSH IDM0084951

Synonyms (44)

Synonym
meteneprost
u-46785
61263-35-2
D02726
meteneprost (usan/inn)
meteneprost [usan:inn]
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-methylene-, (5z,11alpha,13e,15r)-
u 46785
meteneprostum [latin]
(5z,11r,13e,15r)-11,15-dihydroxy-16,16-dimethyl-9-methylen-5,13-prostadiensaeure
9-deoxo-16,16-dimethyl-9-methylene-pge2
u-46,785
9-deoxo-16,16-dimethyl-9-methyleneprostaglandin e2
meteneprostum
7-(5,5-dimethyl-3-hydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-5-heptenoic acid
(z)-7-((1r,2r,3r)-3-hydroxy-2-((e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl)-5-methylenecyclopentyl)-5-heptenoic acid
meteneprostum [inn-latin]
5-heptenoic acid, 7-(5,5-dimethyl-3-hydroxy-2-(3-hydroxy-1-octenyl)cyclopentyl)-
9-deoxy-9-methylene-16,16-dimethyl -pge2
LMFA03010059
9-deoxy-9-methylene-16,16-dimethyl -prostaglandin e2
9-methylene-11r,15s-dihydroxy-16,16-dimethyl-5z,13e-prostadienoic acid
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e,3r)-3-hydroxy-4,4-dimethyloct-1-enyl]-5-methylidenecyclopentyl]hept-5-enoic acid
CHEBI:165325
269eb4r1tv ,
unii-269eb4r1tv
SCHEMBL564226
meteneprost [usan]
meteneprost [mart.]
9-deoxo-16,16-dimethyl-9-methyleneprostaglandin e(sub 2)
(z)-7-[(1r,2r,3r)-3-hydroxy-2-[(e)-(3r)-3-hydroxy-4,4-dimethyl-1-octenyl]-5-methylenecyclopentyl]-5-heptenoic acid
u 46,785
prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-16,16-dimethyl-9-methylene-, (5z,11.alpha.,13e,15r)-
meteneprost [inn]
9-deoxy-9-methylene-16,16-dimethyl prostaglandin e2
AC-31145
HMS3648H05
prosta-5,13-dien-1-oicacid,11,15-dihydroxy-16,16-dimethyl-9-methylene-,(5z,11a,13e,15r)-
CHEMBL3989772
sr-01000946425
SR-01000946425-1
DTXSID001018145
Q27254077
AKOS040755477

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"The effects of intravenous infusions of the stable prostaglandin analogue 9-deoxo-16,16-dimethyl-9-methylene-PGE2 (9-methylene-PGE2) in a dosage of 10 or 24 micrograms/min were studied in the consicious euhydrated, dehydrated, and hyperhydrated with the simultaneous administration of exogenous arginine vasopressin (AVP), sheep."( The prostaglandin-analogue-9-deoxo-16,16-dimethyl-9-methylene-PGE2 inhibits the antidiuretic effect of vasopressin (AVP) in the conscious sheep.
Bygdeman, M; Christensen, NJ; GreƩn, K; Jonasson, H; Leksell, LG; Rundgren, M; Vesterqvist, O; Wallin, CJ, 1984
)
0.27
"5 ml/min) in the dosage of 20 micrograms/min for 2 h in conscious euhydrated man."( Water diuretic effect of intravenously administered 9-deoxo-16, 16-dimethyl-9-methylene-PGE2 in conscious man.
Christensen, NJ; Leksell, LG; Vesterqvist, O; Wallin, CJ, 1984
)
0.27
"A comparative study was conducted to assess the relative efficacy and side effects of 2 dosage schedules using 9-deoxo-16,16-dimethyl-9-methylene PGE2alpha (prostaglandin) for 2nd-trimester abortion."( The vaginal administration of 9-deoxo-16,16-dimethyl-9-methylene PGE2 for second trimester abortion.
Ballard, CA, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
long-chain fatty acidA fatty acid with a chain length ranging from C13 to C22.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (43)

TimeframeStudies, This Drug (%)All Drugs %
pre-199036 (83.72)18.7374
1990's6 (13.95)18.2507
2000's1 (2.33)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.33

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.33 (24.57)
Research Supply Index4.14 (2.92)
Research Growth Index4.29 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.33)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (34.78%)5.53%
Reviews1 (2.17%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (63.04%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]